open access

Vol 2, No 2 (1997)
Untitled
Published online: 1997-01-01
Submitted:
Get Citation

Some questions regarding treatment planning for Cf-252 neutron brachytherapy

A. Miller
DOI: 10.1016/S1428-2267(97)70132-7
·
Rep Pract Oncol Radiother 1997;2(2):51.

open access

Vol 2, No 2 (1997)
Untitled
Published online: 1997-01-01
Submitted:

Abstract

Introduction

The use of Cf-252 isotope in the Lithuanian Cancer Center (LCC) was initiated in late 1987. Low specific activity (0.3–0.7 μg) Cf-252 needles and flexible (1–5 μg) sources have been successfully employed for treatment of many different lesions (gynecology, head and neck, skin etc.). A high activity (0.3–1.5 mg) remote afterloaded source has been mainly used for treatment of advanced gynecological and rectum cancers.

Material and methods

Treatment planning for interstitial brachytherapy with Cf-252 sources. Two types of interstitial sources are available from the vendor (Russia). Technical characteristics of these sources are presented elsewhere. Calculation of gamma and neutron absorbed dose distribution in tissue around needle and seed of flexible assembly were performed by Vtiurin at al. using Monte Carlo simulation. For the last two decades a number of investigators focused their effort on identifying RBE of Cf-252 for different cell cultures and tissues. Riabuchin at al.11 have collected a considerable amount of the radiobiological data, plotted it against combined dose rate of gamma and neutron components and fit this data with following equation.

Lgη = −0.156 × LgPn+γ + 0.952 (1). Reference (prescribed) dose then is calculated in terms of isoeffective dose which is: Diso = Dn+γ × η (2).

The Paris system has been chosen for Cf-252 interstitial brachytherapy chiefly because this system, even though primarily developed for iridium wire, is more suitable then the Manchester system. Treatment planning for HDR remote afterloading Cf-252 brachytherapy This eqiupment has been in use in Lithuanian Cancer Center since late 1987 and has proven to be a safe and reliable device. The unit was design to provide isodose distribution and treatment times somewhat comparable to that of conventional Ir-192 and Co-60 HDR machines. PC based „in house” computer software has been written to calculate two dimensional isodose distribution for a ANET-V insertion. The Manchester system is employed for gyneciogical treatment planning. The plane of calculation passes through the middle of the ovoids and intersects the tandem. The dose is prescribed to the point A.

Result and conclusions

The treatment planning techniques for interstitial and intracavitary Cf-252 brachytherapy are very similar to those for gamma emitting isotopes. Consequently, the problems are the same. We are using two dimensional dose matrix, however in order to be able comprehensivery describe and report a brachytherapy treatment, treatment planning needs to be performed in three dimensions. Otherwise, three dimensional isodose surfaces surrounding an implant can be difficult to interpret and use for a prescription which is based on physicians prior experience.

  • Calibration protocol for Cf-252 sources needs to be developed

  • Single uniform method for dose prescription needs to be identified

Abstract

Introduction

The use of Cf-252 isotope in the Lithuanian Cancer Center (LCC) was initiated in late 1987. Low specific activity (0.3–0.7 μg) Cf-252 needles and flexible (1–5 μg) sources have been successfully employed for treatment of many different lesions (gynecology, head and neck, skin etc.). A high activity (0.3–1.5 mg) remote afterloaded source has been mainly used for treatment of advanced gynecological and rectum cancers.

Material and methods

Treatment planning for interstitial brachytherapy with Cf-252 sources. Two types of interstitial sources are available from the vendor (Russia). Technical characteristics of these sources are presented elsewhere. Calculation of gamma and neutron absorbed dose distribution in tissue around needle and seed of flexible assembly were performed by Vtiurin at al. using Monte Carlo simulation. For the last two decades a number of investigators focused their effort on identifying RBE of Cf-252 for different cell cultures and tissues. Riabuchin at al.11 have collected a considerable amount of the radiobiological data, plotted it against combined dose rate of gamma and neutron components and fit this data with following equation.

Lgη = −0.156 × LgPn+γ + 0.952 (1). Reference (prescribed) dose then is calculated in terms of isoeffective dose which is: Diso = Dn+γ × η (2).

The Paris system has been chosen for Cf-252 interstitial brachytherapy chiefly because this system, even though primarily developed for iridium wire, is more suitable then the Manchester system. Treatment planning for HDR remote afterloading Cf-252 brachytherapy This eqiupment has been in use in Lithuanian Cancer Center since late 1987 and has proven to be a safe and reliable device. The unit was design to provide isodose distribution and treatment times somewhat comparable to that of conventional Ir-192 and Co-60 HDR machines. PC based „in house” computer software has been written to calculate two dimensional isodose distribution for a ANET-V insertion. The Manchester system is employed for gyneciogical treatment planning. The plane of calculation passes through the middle of the ovoids and intersects the tandem. The dose is prescribed to the point A.

Result and conclusions

The treatment planning techniques for interstitial and intracavitary Cf-252 brachytherapy are very similar to those for gamma emitting isotopes. Consequently, the problems are the same. We are using two dimensional dose matrix, however in order to be able comprehensivery describe and report a brachytherapy treatment, treatment planning needs to be performed in three dimensions. Otherwise, three dimensional isodose surfaces surrounding an implant can be difficult to interpret and use for a prescription which is based on physicians prior experience.

  • Calibration protocol for Cf-252 sources needs to be developed

  • Single uniform method for dose prescription needs to be identified

Get Citation
About this article
Title

Some questions regarding treatment planning for Cf-252 neutron brachytherapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 2, No 2 (1997)

Pages

51

Published online

1997-01-01

DOI

10.1016/S1428-2267(97)70132-7

Bibliographic record

Rep Pract Oncol Radiother 1997;2(2):51.

Authors

A. Miller

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl